Omada Health Partners with Eli Lilly for Employer GLP-1 Program
Omada Health announced a partnership with Eli Lilly and Company's Employer Connect program, enabling Omada to offer its GLP-1 Care Track directly to employers. This collaboration provides a new channel for employers to offer weight loss medications like Zepbound with coordinated lifestyle support, alongside Omada's existing pharmacy benefit manager and cash-pay pathways. The initiative aims to address the growing demand for anti-obesity medicines and the challenges employers face in providing consistent coverage, offering transparent costs and predictable structures. Omada's recent survey highlighted significant gaps in patient support and access, with many desiring more guidance and facing high out-of-pocket costs, which Omada's program seeks to bridge.
Key Highlights
- Omada Health partnered with Eli Lilly's Employer Connect program.
- Omada will offer its GLP-1 Care Track directly to employers.
- This adds a new direct-to-employer channel for Omada's GLP-1 solutions.
- The program offers transparent net cost for Zepbound and defined employer contributions.
- Omada's survey found 61% of GLP-1 patients want more provider time.
- 44% of surveyed patients pay over $250 per month for GLP-1 medication.
- Omada members achieved 18.4% average weight loss at one year on GLP-1s.
- Omada's GLP-1 Care Track can now be deployed via three leading PBMs, direct-to-employer, and cash-pay options.